Gaëlle Picarda

Gaëlle Picarda

Auto-generated profile, based on publicly available information

Gaëlle Picarda

Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; and

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2018 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GPGaëlle Picarda
Gaëlle Picarda
CBChris A Benedict
Chris A Benedict
Systems-based based approaches have begun to shed light on extrinsic factors that contribute to immune system variation. Among these, CMV (HHV-5, a β-herpesvirus) imposes a surprisingly profound impact. Most of the world’s population is CMV+, and the virus goes through three distinct infection phases en route to establishing lifelong détente with its host. Immune control of CMV in each phase recruits unique arms of host defense, and in turn the virus employs multiple immune-modulatory strategies that help facilitate the establishment of lifelong persistence. In this review, we explain how CMV shapes immunity and discuss the impact it may have on overall health.

1 May 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GPGaëlle Picarda
Gaëlle Picarda
CCCoraline Chéneau
Coraline Chéneau
JHJean-Marc Humbert
Jean-Marc Humbert
GBGaëlle Bériou
Gaëlle Bériou
PPPaul Pilet
Paul Pilet
FHFranck Albert Halary
Franck Albert Halary
Langerhans cells (LCs) are epithelial APCs that sense danger signals and in turn trigger specific immune responses. In steady-state, they participate in the maintenance of peripheral tolerance to self-antigens whereas under inflammation LCs efficiently trigger immune responses in secondary lymphoid organs. It has been demonstrated in mice that LC-deprived epithelia are rapidly replenished by short half-life langerin-expressing monocyte-derived LCs (MDLCs). These surrogate LCs are thought to be progressively replaced by langerinhigh LCs arising from self-renewing epithelial precursors of hematopoietic origin. How LCs arise from blood monocytes is not fully understood. Hence, we sought to characterize key factors that induce differentiation of langerinhigh-expressing monocyte-derived Langerhans-like cells. We identified GM-CSF and TGF-β1 as key cytokines to generate langerinhigh-expressing cells but only in serum-free conditions. These cells were shown to express the LC-specific TROP-2 and Axl surface markers and contained Birbeck granules. Surprisingly, E-cadherin was not spontaneously expressed by these cells but required a direct contact with keratinocytes to be stably induced. MDLCs induced stronger allogeneic T cell proliferations but released low amounts of inflammatory cytokines upon TLR stimulation compared with donor-paired monocyte-derived dendritic cells. Immature langerinhigh MDLCs were responsive to MIP-3β/CCL20 and CTAC/CCL27 chemokine stimulations. Finally, we demonstrated that those cells behaved as bona fide LCs when inserted in a three-dimensional rebuilt epithelium by becoming activated upon TLR or UV light stimulations. Collectively, these results prompt us to propose these langerinhigh MDLCs as a relevant model to address LC biology–related questions.

30 March 2023
Verified
Other
Open access
GOGuillaume Anthony Odri
Guillaume Anthony Odri
SDSophie Dumoucel
Sophie Dumoucel
GPGaëlle Picarda
Gaëlle Picarda
SBSeverine Battaglia
Severine Battaglia
François LamoureuxFrançois Lamoureux
François Lamoureux
FRFrancoise Redini
Francoise Redini

30 March 2023
Verified
Other
Open access
GOGuillaume Anthony Odri
Guillaume Anthony Odri
SDSophie Dumoucel
Sophie Dumoucel
GPGaëlle Picarda
Gaëlle Picarda
SBSeverine Battaglia
Severine Battaglia
François LamoureuxFrançois Lamoureux
François Lamoureux
FRFrancoise Redini
Francoise Redini

30 March 2023
Verified
Other
Open access
GOGuillaume Anthony Odri
Guillaume Anthony Odri
SDSophie Dumoucel
Sophie Dumoucel
GPGaëlle Picarda
Gaëlle Picarda
SBSeverine Battaglia
Severine Battaglia
François LamoureuxFrançois Lamoureux
François Lamoureux
FRFrancoise Redini
Francoise Redini
Ewing's sarcoma (ES) is the second most frequent pediatric bone tumor also arising in soft tissues (15% of cases). The prognosis of patients with clinically detectable metastases at diagnosis, not responding to therapy or with disease relapse, is still very poor. Among new therapeutic approaches, bisphosphonates represent promising adjuvant molecules to chemotherapy to limit the osteolytic component of bone tumors and to protect from bone metastases. The combined effects of zoledronic acid and mafosfamide were investigated on cell proliferation, viability, apoptosis, and cell cycle distribution of human ES cell lines differing in their p53 and p16/ink4 status. ES models were developed to reproduce both soft tissue and intraosseous tumor development. Mice were treated with 100 μg/kg zoledronic acid (two or four times per week) and/or ifosfamide (30 mg/kg, one to three cycles of three injections). ES cell lines showed different sensitivities to zoledronic acid and mafosfamide at the cell proliferation level, with no correlation with their molecular status. Both drugs induced cell cycle arrest, but in the S or G2M phase, respectively. In vivo, zoledronic acid had no effect on soft tissue tumor progression, although it dramatically inhibited ES development in bone. When combined with ifosfamide, zoledronic acid exerted synergistic effects in the soft tissue model: Its combination with one cycle of ifosfamide resulted in an inhibitory effect similar to three cycles of ifosfamide alone. This very promising result could allow clinicians to diminish the doses of chemotherapy. Cancer Res; 70(19); 7610–9. ©2010 AACR.

30 March 2023
Verified
Other
Open access
GOGuillaume Anthony Odri
Guillaume Anthony Odri
SDSophie Dumoucel
Sophie Dumoucel
GPGaëlle Picarda
Gaëlle Picarda
SBSeverine Battaglia
Severine Battaglia
François LamoureuxFrançois Lamoureux
François Lamoureux
FRFrancoise Redini
Francoise Redini
Ewing's sarcoma (ES) is the second most frequent pediatric bone tumor also arising in soft tissues (15% of cases). The prognosis of patients with clinically detectable metastases at diagnosis, not responding to therapy or with disease relapse, is still very poor. Among new therapeutic approaches, bisphosphonates represent promising adjuvant molecules to chemotherapy to limit the osteolytic component of bone tumors and to protect from bone metastases. The combined effects of zoledronic acid and mafosfamide were investigated on cell proliferation, viability, apoptosis, and cell cycle distribution of human ES cell lines differing in their p53 and p16/ink4 status. ES models were developed to reproduce both soft tissue and intraosseous tumor development. Mice were treated with 100 μg/kg zoledronic acid (two or four times per week) and/or ifosfamide (30 mg/kg, one to three cycles of three injections). ES cell lines showed different sensitivities to zoledronic acid and mafosfamide at the cell proliferation level, with no correlation with their molecular status. Both drugs induced cell cycle arrest, but in the S or G2M phase, respectively. In vivo, zoledronic acid had no effect on soft tissue tumor progression, although it dramatically inhibited ES development in bone. When combined with ifosfamide, zoledronic acid exerted synergistic effects in the soft tissue model: Its combination with one cycle of ifosfamide resulted in an inhibitory effect similar to three cycles of ifosfamide alone. This very promising result could allow clinicians to diminish the doses of chemotherapy. Cancer Res; 70(19); 7610–9. ©2010 AACR.